Bio-Path Holdings (BPTH) AI Stock Analysis

• Market Cap: $1.29M
• Dividend Yield: N/A
• Average Volume (3M): 49.24K
• Price to Earnings (P/E): ―
• Beta (1Y): -0.72
• Revenue Growth: N/A
• EPS Growth: 79.79%
• Country: US
• Employees: 10
• Sector: Healthcare
• Sector Strength: 40
• Industry: Biotechnology
• EPS (TTM): -0.40
• Shares Outstanding: 8,307,892
• 10 Day Avg. Volume: 53,855
• 30 Day Avg. Volume: 49,239
• PEG Ratio: >-0.01
• Price to Book (P/B): -0.41
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -0.12
• Enterprise Value/Market Cap: 1.13
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: -0.06
• 1Y Price Target: $2.00
• Price Target Upside: 1233.33% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 1

• Rating: 37 Underperform
• Price Target: ―

Bio-Path Holdings' stock is significantly challenged by poor financial performance, characterized by no revenue and high cash burn. The technical indicators also suggest a bearish trend. However, the promising pre-clinical results offer a glimmer of hope for future prospects. The negative P/E ratio and lack of dividend yield further contribute to a low valuation score. Overall, the stock is risky, with financial sustainability being a major concern.

Bio-Path Holdings Business Overview & Revenue Model

Company Description

Bio-Path Holdings, Inc. is a biotechnology company that develops RNAi nanoparticle drug products to treat various cancer types. The company operates within the biotechnology and pharmaceutical sectors, focusing on the development of therapeutics for cancer treatment. Its core products include pre-clinical and clinical stage candidates such as BP1001, BP1002, and BP1003, which are designed to address unmet medical needs in oncology.

How the Company Makes Money

Bio-Path Holdings makes money primarily through the development and commercialization of its proprietary drug candidates. The company's revenue model includes licensing agreements, partnerships with larger pharmaceutical firms, and potential future sales of approved drugs. Bio-Path may also receive milestone payments and royalties from these partnerships and collaborations as their drug candidates advance through clinical trials and, if successful, reach the market. Additionally, the company might engage in raising capital through stock offerings to fund its research and development efforts.

Bio-Path Holdings Financial Statement Overview

Summary

Bio-Path Holdings faces significant financial challenges with no revenue generation, persistent losses, and reliance on external financing. The high cash burn rate coupled with declining equity suggests substantial risks in maintaining operations without strategic shifts or new revenue streams.

Income Statement

The company has not generated any revenue over the past years, which is a significant concern for sustainability. The net losses persist with no visible revenue growth, indicating potential financial instability.

Balance Sheet

The company has a very low equity base with rising liabilities, leading to a deteriorating debt-to-equity ratio. The equity ratio has decreased significantly over the years, which suggests increased financial risk.

Cash Flow

The operating cash flows are negative, reflecting a high burn rate without corresponding inflows from operations. Financing activities have been the primary source of cash, raising concerns about long-term viability without revenue generation.

Breakdown	Dec 2024	Dec 2023	Dec 2022	Dec 2021	Dec 2020
Income Statement
Total Revenue	0.00	0.00	0.00	0.00	0.00
Gross Profit	0.00	-178.00K	-178.00K	-161.00K	-151.00K
EBITDA	0.00	-15.76M	-13.69M	-10.28M	-10.73M
Net Income	-9.89M	-16.08M	-13.84M	-10.44M	-10.86M
Balance Sheet
Total Assets	3.88M	3.22M	15.97M	26.57M	16.48M
Cash, Cash Equivalents and Short-Term Investments	1.17M	1.05M	10.38M	23.77M	13.76M
Total Debt	83.00K	113.00K	221.00K	235.00K	330.00K
Total Liabilities	3.73M	2.78M	1.80M	1.11M	1.41M
Stockholders Equity	154.00K	441.00K	14.17M	25.46M	15.07M
Cash Flow
Free Cash Flow	-10.57M	-11.54M	-15.12M	-9.99M	-10.96M
Operating Cash Flow	-10.57M	-11.54M	-15.10M	-9.92M	-10.96M
Investing Cash Flow	0.00	0.00	-21.00K	-70.00K	0.00
Financing Cash Flow	10.70M	2.20M	1.73M	20.01M	4.29M

Bio-Path Holdings Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 0.15
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BPTH, the sentiment is Negative. The current price of 0.15 is below the 20-day moving average (MA) of 0.16, below the 50-day MA of 0.18, and below the 200-day MA of 0.49, indicating a bearish trend. The MACD of >-0.01 indicates Positive momentum. The RSI at 38.90 is Neutral, neither overbought nor oversold. The STOCH value of 20.83 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for BPTH.

Bio-Path Holdings Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	52 Neutral	$7.47B	0.53	-62.70%	2.38%	14.92%	0.82%
ISPC	46 Neutral	$4.22M	―	-265.37%	―	-13.05%	49.76%
UPC	45 Neutral	$2.26M	―	2.66%	―	-27.81%	―
BPTH	37 Underperform	$1.29M	―	-3325.71%	―	―	79.79%
RSLS	37 Underperform	$5.56M	―	-120.16%	―	-7.74%	93.25%
ONCO	33 Underperform	$1.89M	―	-237.69%	―	―	-97.16%
WINT	28 Underperform	$10.96M	―	-120.01%	―	―	97.84%

Bio-Path Holdings Corporate Events

Bio-Path Holdings Reports Promising Pre-Clinical Results

On March 18, 2025, Bio-Path Holdings announced promising pre-clinical results for BP1001-A, indicating its potential as a treatment for obesity in Type 2 diabetes patients. The studies showed that BP1001-A attenuated fatty acid-induced insulin resistance and restored insulin sensitivity in muscle progenitor and skeletal muscle fiber cell models. This progress suggests a new application for BP1001-A beyond current weight loss drugs, potentially offering a novel therapeutic option for reducing glucose levels in patients with Type 2 diabetes. Bio-Path plans to advance these studies and file for regulatory designations to accelerate approval, with a final pre-clinical mouse model study expected in the first half of 2025 and an IND filing by year-end.